Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study (Q86047554)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study (English)

1 reference

23 February 2020

1 reference

ChEBI release 2020-05-28

1 reference

S Sha

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

D Polidori

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

2

1 reference

23 February 2020

K Farrell

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

3

1 reference

23 February 2020

A Ghosh

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

4

1 reference

23 February 2020

J Natarajan

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

5

1 reference

23 February 2020

N Vaccaro

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

6

1 reference

23 February 2020

J Pinheiro

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

7

1 reference

23 February 2020

P Rothenberg

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

8

1 reference

23 February 2020

L Plum-Mörschel

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

5 January 2015

1 reference

Diabetes, Obesity and Metabolism

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

188-197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421015%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

2

1 reference

Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study.

23 February 2020

cites work

1 reference

12 December 2020

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

12 December 2020

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

1 reference

12 December 2020

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

12 December 2020

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

12 December 2020

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

1 reference

12 December 2020

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

12 December 2020

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

12 December 2020

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

12 December 2020

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus

1 reference

12 December 2020

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

1 reference

12 December 2020

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

1 reference

12 December 2020

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

12 December 2020

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

12 December 2020

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

1 reference

12 December 2020

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

12 December 2020

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

1 reference

12 December 2020

Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus

1 reference

12 December 2020

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Clinical implication of SGLT2 inhibitors in type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

1 reference

12 December 2020

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

1 reference

12 December 2020

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

1 reference

12 December 2020

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

1 reference

12 December 2020